Brainstorm Cell Therapeutics (BCLI) versus Its Peers Critical Comparison
Brainstorm Cell Therapeutics (NASDAQ: BCLI) is one of 187 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Brainstorm Cell Therapeutics to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Earnings and Valuation
This table compares Brainstorm Cell Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Brainstorm Cell Therapeutics||N/A||-$4.98 million||-11.74|
|Brainstorm Cell Therapeutics Competitors||$217.40 million||-$39.40 million||-63.18|
This table compares Brainstorm Cell Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics||N/A||-76.45%||-59.84%|
|Brainstorm Cell Therapeutics Competitors||-4,594.03%||-35.12%||-43.24%|
Institutional & Insider Ownership
13.1% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 24.7% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Brainstorm Cell Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics’ competitors have a beta of 1.48, suggesting that their average share price is 48% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Brainstorm Cell Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics||0||0||1||0||3.00|
|Brainstorm Cell Therapeutics Competitors||572||2507||6736||133||2.65|
Brainstorm Cell Therapeutics currently has a consensus target price of $9.00, suggesting a potential upside of 147.25%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.10%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Brainstorm Cell Therapeutics is more favorable than its competitors.
Brainstorm Cell Therapeutics beats its competitors on 8 of the 13 factors compared.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.